Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

Infection with SARS‐CoV‐2 elicits robust antibody responses in some patients, with a
majority of the response directed at the receptor binding domain (RBD) of the spike surface …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …